MiNK Therapeutics (INKT) vs LeonaBio (LONA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
LeonaBio (LONA) has outperformed MiNK Therapeutics (INKT) over the past year, gaining 46.7% versus a loss of 24.6%. Over five years, INKT leads with a -90.8% price change compared with -94.0% for LONA. MiNK Therapeutics is the larger company by market cap ($54.7 million vs $54.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INKT | LONA |
|---|---|---|
| Share price | $10.72 | $5.75 |
| Market cap | $54.70M | $54.17M |
| 1-day change | -2.55% | 0.00% |
| YTD return | -1.35% | -24.04% |
| 1-year return | -24.61% | +46.68% |
| 5-year return | -90.83% | -93.99% |
| EPS (TTM) | $-2.35 | $-23.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.93 | $14.21 |
| 52-week low | $8.48 | $2.21 |
| Distance from 52-week high | -36.67% | -59.54% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +263.81% | +201.39% |
| Average volume | 13.80K | 185.45K |
| Shares outstanding | 5.10M | 9.42M |
| Employees | 15 | 19 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LONA has outperformed INKT by 71.3 percentage points over the past year.
About MiNK Therapeutics
INKT stock →MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 15 employees
About LeonaBio
LONA stock →LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 19 employees
INKT vs LONA FAQ
Which is bigger, MiNK Therapeutics or LeonaBio?
MiNK Therapeutics (INKT) is larger, with a market capitalization of $54.70M compared with $54.17M for LeonaBio (LONA).
Which stock has performed better over the past year, INKT or LONA?
LONA returned +46.68% over the past 12 months, compared with -24.61% for INKT (price return, excluding dividends). Past performance does not predict future results.
Are MiNK Therapeutics and LeonaBio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.